Molecular Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample Type (Blood, Urine), Technology (PCR, INAAT), Application (Infectious, Oncology), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2028
The molecular diagnostics market is valued at an estimated USD 16.6 billion in 2023 and is projected to reach USD 28.6 billion by 2028 at a CAGR of 11.4% during the forecast period. Diseases such as tuberculosis, HIV/AIDS, hepatitis, sexually transmitted infections, and respiratory infections require an accurate and timely diagnosis for effective treatment and control. Molecular diagnostics play a crucial role in the detection and monitoring of these infectious diseases, driving the growth of the market in this area.
Apart from infectious disease diagnostics, molecular diagnostic techniques are increasingly being used to enhance patient management, particularly in the field of cancer. The growing prevalence of cancer globally will increase the number of specimens tested, thus creating a demand for new diagnostic procedures, including molecular diagnostics.
“Blood, serum, and plasma segment accounted for the highest growth rate in the molecular diagnostics market, by sample type, during the forecast period”
The molecular diagnostics market is bifurcated into blood, serum, and plasma, urine, and other sample types on the basis of sample type. The blood, serum, and plasma segment in molecular diagnostics is experiencing substantial growth, largely driven by the increased demand for infectious disease testing. Infectious diseases pose significant global health challenges, and the accurate and timely diagnosis of these conditions is crucial for effective disease management and public health measures.
Plasma and serum samples provide several advantages for infectious disease testing. Plasma and serum samples have wide-ranging diagnostic applications in infectious diseases, including viral, bacterial, fungal, and parasitic infections. They aid in early diagnosis, appropriate treatment selection, and the assessment of treatment response. Moreover, Blood-based molecular diagnostics have demonstrated clinical utility across a broad range of applications, including genetic testing, infectious disease diagnosis, cancer diagnostics, and monitoring disease progression.
“Oncology testing segment accounted for the highest growth rate in the molecular diagnostics market, by application, during the forecast period”
The global molecular diagnostics market is bifurcated into infectious disease diagnostics, oncology testing, genetic testing, and other applications. Oncology testing segment is currently witnessing the highest growth rate within the molecular diagnostics market, reflecting the increasing importance of precision medicine and personalized approaches in cancer care. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. Molecular diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage.
Through various strategic developments, pharmaceutical companies and molecular diagnostic manufacturers have increasingly focused on integrating their synergies to develop personalized medicine and companion diagnostic assays that can support the monitoring of a patient’s response to a given drug therapy. This is a major factor boosting the growth of the oncology testing segment. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.
“Asia Pacific: The fastest-growing region molecular diagnostics market”
The global molecular diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in this region have witnessed growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies in the Asia Pacific countries. These factors are expected to provide significant growth opportunities for molecular diagnostic companies operating in this region.
The Asia Pacific, which has become a medical tourism hub, is considered one of the fastest-growing markets for medical procedures and devices. Low infrastructure and treatment costs and the availability of highly educated physicians have driven medical tourists to these countries, which is a major factor driving the growth of the molecular diagnostics market in this region.
The break-up of the profile of primary participants in the molecular diagnostics market:
Research Coverage:
This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services & software), test type (lab tests and PoC tests), sample type (blood, serum, and plasma, urine, and other sample types), application (infectious disease diagnostics (hepatitis, HIV, CT/NG, HAI, HPV, tuberculosis, influenza, and other infectious diseases), oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancer testing), genetic testing, and other applications, technology (polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, in situ hybridization, DNA microarrays, and other technologies), end user (diagnostic laboratories, hospitals & clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product & service launches, and recent developments associated with the molecular diagnostics market. Competitive analysis of upcoming startups in the molecular diagnostics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
Apart from infectious disease diagnostics, molecular diagnostic techniques are increasingly being used to enhance patient management, particularly in the field of cancer. The growing prevalence of cancer globally will increase the number of specimens tested, thus creating a demand for new diagnostic procedures, including molecular diagnostics.
“Blood, serum, and plasma segment accounted for the highest growth rate in the molecular diagnostics market, by sample type, during the forecast period”
The molecular diagnostics market is bifurcated into blood, serum, and plasma, urine, and other sample types on the basis of sample type. The blood, serum, and plasma segment in molecular diagnostics is experiencing substantial growth, largely driven by the increased demand for infectious disease testing. Infectious diseases pose significant global health challenges, and the accurate and timely diagnosis of these conditions is crucial for effective disease management and public health measures.
Plasma and serum samples provide several advantages for infectious disease testing. Plasma and serum samples have wide-ranging diagnostic applications in infectious diseases, including viral, bacterial, fungal, and parasitic infections. They aid in early diagnosis, appropriate treatment selection, and the assessment of treatment response. Moreover, Blood-based molecular diagnostics have demonstrated clinical utility across a broad range of applications, including genetic testing, infectious disease diagnosis, cancer diagnostics, and monitoring disease progression.
“Oncology testing segment accounted for the highest growth rate in the molecular diagnostics market, by application, during the forecast period”
The global molecular diagnostics market is bifurcated into infectious disease diagnostics, oncology testing, genetic testing, and other applications. Oncology testing segment is currently witnessing the highest growth rate within the molecular diagnostics market, reflecting the increasing importance of precision medicine and personalized approaches in cancer care. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. Molecular diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage.
Through various strategic developments, pharmaceutical companies and molecular diagnostic manufacturers have increasingly focused on integrating their synergies to develop personalized medicine and companion diagnostic assays that can support the monitoring of a patient’s response to a given drug therapy. This is a major factor boosting the growth of the oncology testing segment. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.
“Asia Pacific: The fastest-growing region molecular diagnostics market”
The global molecular diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in this region have witnessed growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies in the Asia Pacific countries. These factors are expected to provide significant growth opportunities for molecular diagnostic companies operating in this region.
The Asia Pacific, which has become a medical tourism hub, is considered one of the fastest-growing markets for medical procedures and devices. Low infrastructure and treatment costs and the availability of highly educated physicians have driven medical tourists to these countries, which is a major factor driving the growth of the molecular diagnostics market in this region.
The break-up of the profile of primary participants in the molecular diagnostics market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%
Research Coverage:
This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services & software), test type (lab tests and PoC tests), sample type (blood, serum, and plasma, urine, and other sample types), application (infectious disease diagnostics (hepatitis, HIV, CT/NG, HAI, HPV, tuberculosis, influenza, and other infectious diseases), oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancer testing), genetic testing, and other applications, technology (polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, in situ hybridization, DNA microarrays, and other technologies), end user (diagnostic laboratories, hospitals & clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product & service launches, and recent developments associated with the molecular diagnostics market. Competitive analysis of upcoming startups in the molecular diagnostics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (increasing prevalence of infectious diseases and cancer globally, rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies, growing awareness of early disease diagnosis in developing countries, rising technological advancements in molecular diagnostics in recent years, and increasing use of PoC diagnostic tests in homecare settings and hospitals), restraints (unfavorable reimbursement scenario for diagnostic companies and high cost of molecular diagnostic instruments), opportunities (growing significance of companion diagnostics in drug development process and growth opportunities for molecular diagnostic companies in emerging economies), and challenges (changing regulatory landscape for IVD and molecular diagnostics in US and European Union, operational barriers and shortage of skills across major markets, and introduction of alternative technologies for disease detection and diagnosis) influencing the growth of the molecular diagnostics market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the molecular diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the molecular diagnostics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), and bioM?rieux (France), among others in the molecular diagnostics market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION
1.3.2 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 MARKET LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Company presentations and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT OF MOLECULAR DIAGNOSTICS MARKET
2.10 IMPACT OF ECONOMIC RECESSION ON MOLECULAR DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET
4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 16 REAGENTS & KITS TO DOMINATE MOLECULAR DIAGNOSTICS MARKET IN 2028
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028
FIGURE 17 LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028
4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028
FIGURE 18 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028
FIGURE 19 PCR SEGMENT TO DOMINATE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD
4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028
FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028
4.7 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.8 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR DIAGNOSTICS MARKET DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer globally
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies
5.2.1.3 Growing awareness regarding early disease diagnosis in developing countries
5.2.1.4 Rising technological advancements in molecular diagnostics in recent years
5.2.1.5 Increasing use of PoC diagnostic tests in homecare settings and hospitals
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
5.2.2.2 High cost of molecular diagnostic instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics in drug development process
5.2.3.2 Increasing growth opportunities for molecular diagnostics companies in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape for IVD and molecular diagnostics in US and European Union
5.2.4.2 Operational barriers and shortage of skills across major markets
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
5.3 PRICING ANALYSIS
5.3.1 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER
TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS
5.4 PATENT ANALYSIS
FIGURE 24 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022)
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 26 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP ANALYSIS
FIGURE 27 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP ANALYSIS
5.7.1 MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.4.2 Mexico
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 11 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SHIFT IN MOLECULAR DIAGNOSTICS MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%)
5.15.2 BUYING CRITERIA
FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
5.16 CASE STUDY ANALYSIS
FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 14 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
6.2 REAGENTS & KITS
6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET
TABLE 16 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
TABLE 17 KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET
TABLE 18 MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH
TABLE 19 MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2021–2028 (USD MILLION)
7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE
7.1 INTRODUCTION
TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
7.1.1 PRIMARY NOTES
7.1.1.1 Key industry insights
7.2 LAB TESTS
7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
TABLE 21 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2021–2028 (USD MILLION)
7.3 POC TESTS
7.3.1 FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH
TABLE 22 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021–2028 (USD MILLION)
8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE
8.1 INTRODUCTION
TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 24 MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2028 (USD MILLION)
8.3 URINE
8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
TABLE 25 MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
8.4 OTHER SAMPLE TYPES
TABLE 26 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)
9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.1.1 PRIMARY NOTES
9.1.1.1 Key industry insights
TABLE 27 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
9.2 POLYMERASE CHAIN REACTION
9.2.1 GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET
TABLE 28 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION)
9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
9.3.1 COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET
TABLE 29 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
9.4.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
TABLE 30 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
9.5 IN SITU HYBRIDIZATION
9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
TABLE 31 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION)
9.6 DNA MICROARRAYS
9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021–2028 (USD MILLION)
9.7 OTHER TECHNOLOGIES
TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
10.1 INTRODUCTION
TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
10.2 INFECTIOUS DISEASE DIAGNOSTICS
TABLE 35 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
10.2.1 HEPATITIS
10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment
TABLE 37 HEPATITIS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 38 HEPATITIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.2 HIV
10.2.2.1 Increased global prevalence of HIV to propel segment
TABLE 39 HIV MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 40 HIV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.3 CT/NG
10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally
TABLE 41 CT/NG MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 42 CT/NG MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.4 HAIS
10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market
TABLE 43 HAIS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 44 HAIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.5 HPV
10.2.5.1 Technological advancements for preventing HPV infections to augment market
TABLE 45 HPV MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 46 HPV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.6 TUBERCULOSIS
10.2.6.1 Increasing burden of TB globally to propel market
TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.7 INFLUENZA
10.2.7.1 Rising focus on decreasing spread of influenza to propel segment
TABLE 49 INFLUENZA MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 50 INFLUENZA MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.8 OTHER INFECTIOUS DISEASES
TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3 ONCOLOGY TESTING
TABLE 52 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 53 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2021–2028 (USD MILLION)
10.3.1 BREAST CANCER
10.3.1.1 Increasing prevalence of breast cancer among females to boost market
TABLE 54 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 55 BREAST CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3.2 COLORECTAL CANCER
10.3.2.1 Rising focus on development of companion diagnostic assays to fuel market
TABLE 56 COLORECTAL CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3.3 LUNG CANCER
10.3.3.1 Increasing research for lung cancer biomarkers to drive market
TABLE 57 LUNG CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3.4 PROSTATE CANCER
10.3.4.1 Advancements in genomic technologies for development of new biomarkers to aid market
TABLE 58 PROSTATE CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3.5 OTHER CANCERS
TABLE 59 GLOBAL CANCER INCIDENCE, 2020
TABLE 60 OTHER CANCERS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.4 GENETIC TESTING
10.4.1 DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET
TABLE 61 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021–2028 (USD MILLION)
10.5 OTHER APPLICATIONS
TABLE 62 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10.6 COVID-19
10.6.1 DECLINING CASES OF COVID-19 TO HINDER MARKET
TABLE 63 MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION)
11 MOLECULAR DIAGNOSTICS MARKET, BY END USER
11.1 INTRODUCTION
TABLE 64 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2 DIAGNOSTIC LABORATORIES
11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
TABLE 65 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
11.3 HOSPITALS & CLINICS
11.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
TABLE 66 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION)
11.4 OTHER END USERS
TABLE 67 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
12 MOLECULAR DIAGNOSTICS MARKET, BY REGION
12.1 INTRODUCTION
TABLE 68 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 31 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 71 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 72 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 73 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 74 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 76 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
12.2.2 US
12.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 78 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 79 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 80 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 81 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 82 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.3 CANADA
12.2.3.1 High availability of funding for genomics research to fuel market
TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 84 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 86 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 88 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3 EUROPE
TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 91 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 92 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 93 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 94 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 95 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
12.3.2 GERMANY
12.3.2.1 Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market
TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 98 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 99 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 100 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 101 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.3 UK
12.3.3.1 Growing number of accredited diagnostic laboratories to fuel market
TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 104 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 105 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 106 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.4 FRANCE
12.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 110 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 111 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 112 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.5 ITALY
12.3.5.1 Adoption of advanced diagnostic technologies to support market
TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 116 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 117 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 118 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.6 SPAIN
12.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 122 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 123 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 124 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.7 RUSSIA
12.3.7.1 Increasing access to quality healthcare and growing incidence of infectious diseases to aid market
TABLE 127 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 128 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 129 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 130 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.8 REST OF EUROPE
TABLE 133 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 134 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 135 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 136 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 138 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4 ASIA PACIFIC
FIGURE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 139 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 141 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 142 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 143 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 144 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 145 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Rapid economic growth and greater public access to modern healthcare to drive market
TABLE 147 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 148 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 149 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 150 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 151 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 152 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.3 JAPAN
12.4.3.1 Universal healthcare reimbursement policy to support market
TABLE 153 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 154 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 155 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 156 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 158 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.4 INDIA
12.4.4.1 Increased private & public investments and large patient population to drive market
TABLE 159 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 160 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 161 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 162 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 163 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 164 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.5 AUSTRALIA
12.4.5.1 High prevalence of infectious diseases to fuel market
TABLE 165 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 166 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 167 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 168 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 169 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 170 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.6 REST OF ASIA PACIFIC
TABLE 171 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5 LATIN AMERICA
TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 178 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 179 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 180 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 181 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 182 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 183 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 184 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5.1 IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
TABLE 185 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 186 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 187 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 188 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 189 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5.3 MEXICO
12.5.3.1 Improving accessibility and affordability of healthcare services to aid market
TABLE 191 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 192 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 193 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 194 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 195 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 196 MEXICO: MOLECULAR DIAG
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION
1.3.2 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 MARKET LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Company presentations and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT OF MOLECULAR DIAGNOSTICS MARKET
2.10 IMPACT OF ECONOMIC RECESSION ON MOLECULAR DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET
4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 16 REAGENTS & KITS TO DOMINATE MOLECULAR DIAGNOSTICS MARKET IN 2028
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028
FIGURE 17 LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028
4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028
FIGURE 18 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028
FIGURE 19 PCR SEGMENT TO DOMINATE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD
4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028
FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028
4.7 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.8 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR DIAGNOSTICS MARKET DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer globally
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies
5.2.1.3 Growing awareness regarding early disease diagnosis in developing countries
5.2.1.4 Rising technological advancements in molecular diagnostics in recent years
5.2.1.5 Increasing use of PoC diagnostic tests in homecare settings and hospitals
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
5.2.2.2 High cost of molecular diagnostic instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics in drug development process
5.2.3.2 Increasing growth opportunities for molecular diagnostics companies in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape for IVD and molecular diagnostics in US and European Union
5.2.4.2 Operational barriers and shortage of skills across major markets
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
5.3 PRICING ANALYSIS
5.3.1 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER
TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS
5.4 PATENT ANALYSIS
FIGURE 24 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022)
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 26 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP ANALYSIS
FIGURE 27 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP ANALYSIS
5.7.1 MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.4.2 Mexico
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 11 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SHIFT IN MOLECULAR DIAGNOSTICS MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%)
5.15.2 BUYING CRITERIA
FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
5.16 CASE STUDY ANALYSIS
FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 14 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
6.2 REAGENTS & KITS
6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET
TABLE 16 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
TABLE 17 KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET
TABLE 18 MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH
TABLE 19 MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2021–2028 (USD MILLION)
7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE
7.1 INTRODUCTION
TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
7.1.1 PRIMARY NOTES
7.1.1.1 Key industry insights
7.2 LAB TESTS
7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
TABLE 21 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2021–2028 (USD MILLION)
7.3 POC TESTS
7.3.1 FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH
TABLE 22 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021–2028 (USD MILLION)
8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE
8.1 INTRODUCTION
TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 24 MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2028 (USD MILLION)
8.3 URINE
8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
TABLE 25 MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
8.4 OTHER SAMPLE TYPES
TABLE 26 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)
9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.1.1 PRIMARY NOTES
9.1.1.1 Key industry insights
TABLE 27 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
9.2 POLYMERASE CHAIN REACTION
9.2.1 GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET
TABLE 28 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION)
9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
9.3.1 COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET
TABLE 29 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
9.4.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
TABLE 30 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
9.5 IN SITU HYBRIDIZATION
9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
TABLE 31 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION)
9.6 DNA MICROARRAYS
9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021–2028 (USD MILLION)
9.7 OTHER TECHNOLOGIES
TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
10.1 INTRODUCTION
TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
10.2 INFECTIOUS DISEASE DIAGNOSTICS
TABLE 35 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
10.2.1 HEPATITIS
10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment
TABLE 37 HEPATITIS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 38 HEPATITIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.2 HIV
10.2.2.1 Increased global prevalence of HIV to propel segment
TABLE 39 HIV MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 40 HIV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.3 CT/NG
10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally
TABLE 41 CT/NG MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 42 CT/NG MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.4 HAIS
10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market
TABLE 43 HAIS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 44 HAIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.5 HPV
10.2.5.1 Technological advancements for preventing HPV infections to augment market
TABLE 45 HPV MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 46 HPV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.6 TUBERCULOSIS
10.2.6.1 Increasing burden of TB globally to propel market
TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.7 INFLUENZA
10.2.7.1 Rising focus on decreasing spread of influenza to propel segment
TABLE 49 INFLUENZA MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 50 INFLUENZA MARKET, BY REGION, 2021–2028 (MILLION TESTS)
10.2.8 OTHER INFECTIOUS DISEASES
TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3 ONCOLOGY TESTING
TABLE 52 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 53 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2021–2028 (USD MILLION)
10.3.1 BREAST CANCER
10.3.1.1 Increasing prevalence of breast cancer among females to boost market
TABLE 54 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 55 BREAST CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3.2 COLORECTAL CANCER
10.3.2.1 Rising focus on development of companion diagnostic assays to fuel market
TABLE 56 COLORECTAL CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3.3 LUNG CANCER
10.3.3.1 Increasing research for lung cancer biomarkers to drive market
TABLE 57 LUNG CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3.4 PROSTATE CANCER
10.3.4.1 Advancements in genomic technologies for development of new biomarkers to aid market
TABLE 58 PROSTATE CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
10.3.5 OTHER CANCERS
TABLE 59 GLOBAL CANCER INCIDENCE, 2020
TABLE 60 OTHER CANCERS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.4 GENETIC TESTING
10.4.1 DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET
TABLE 61 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021–2028 (USD MILLION)
10.5 OTHER APPLICATIONS
TABLE 62 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10.6 COVID-19
10.6.1 DECLINING CASES OF COVID-19 TO HINDER MARKET
TABLE 63 MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION)
11 MOLECULAR DIAGNOSTICS MARKET, BY END USER
11.1 INTRODUCTION
TABLE 64 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2 DIAGNOSTIC LABORATORIES
11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
TABLE 65 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
11.3 HOSPITALS & CLINICS
11.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
TABLE 66 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION)
11.4 OTHER END USERS
TABLE 67 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
12 MOLECULAR DIAGNOSTICS MARKET, BY REGION
12.1 INTRODUCTION
TABLE 68 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 31 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 71 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 72 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 73 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 74 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 76 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
12.2.2 US
12.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 78 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 79 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 80 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 81 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 82 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.3 CANADA
12.2.3.1 High availability of funding for genomics research to fuel market
TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 84 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 86 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 88 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3 EUROPE
TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 91 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 92 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 93 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 94 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 95 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
12.3.2 GERMANY
12.3.2.1 Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market
TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 98 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 99 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 100 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 101 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.3 UK
12.3.3.1 Growing number of accredited diagnostic laboratories to fuel market
TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 104 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 105 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 106 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.4 FRANCE
12.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 110 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 111 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 112 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.5 ITALY
12.3.5.1 Adoption of advanced diagnostic technologies to support market
TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 116 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 117 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 118 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.6 SPAIN
12.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 122 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 123 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 124 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.7 RUSSIA
12.3.7.1 Increasing access to quality healthcare and growing incidence of infectious diseases to aid market
TABLE 127 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 128 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 129 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 130 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.8 REST OF EUROPE
TABLE 133 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 134 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 135 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 136 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 138 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4 ASIA PACIFIC
FIGURE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 139 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 141 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 142 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 143 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 144 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 145 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Rapid economic growth and greater public access to modern healthcare to drive market
TABLE 147 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 148 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 149 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 150 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 151 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 152 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.3 JAPAN
12.4.3.1 Universal healthcare reimbursement policy to support market
TABLE 153 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 154 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 155 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 156 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 158 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.4 INDIA
12.4.4.1 Increased private & public investments and large patient population to drive market
TABLE 159 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 160 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 161 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 162 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 163 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 164 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.5 AUSTRALIA
12.4.5.1 High prevalence of infectious diseases to fuel market
TABLE 165 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 166 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 167 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 168 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 169 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 170 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.6 REST OF ASIA PACIFIC
TABLE 171 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5 LATIN AMERICA
TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 178 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 179 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 180 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 181 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 182 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 183 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 184 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5.1 IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
TABLE 185 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 186 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 187 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 188 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 189 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5.3 MEXICO
12.5.3.1 Improving accessibility and affordability of healthcare services to aid market
TABLE 191 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 192 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 193 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 194 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 195 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 196 MEXICO: MOLECULAR DIAG
Molecular diagnostic tests are the tests that access the biological makeup at genetic level to identify the predisposition of an individual to a particular disease and to diagnose it.
The global molecular diagnostics market size, in terms of value, is expected to grow from $XX billion in 2013 to $XX billion by 2018, at a CAGR of XX% from 2013 to 2018.
This market is driven by the increasing prevalence of chronic diseases, augmented awareness and acceptance of personalized medicine and companion diagnostics, advancements in molecular techniques, inherited disease testing, and prenatal testing. However, persistent reimbursement issues and delay in approvals of molecular diagnostic tests are expected to curb the growth of this market.
Market dynamics
The molecular diagnostics market progresses with the advancement in the technology. New tests and new instruments to perform these advanced molecular diagnostic tests, automated analysis along with the rise in chronic infections, increasing investments in R&D, growing geriatric population, increasing demand for personalized medicines, and rising R&D activities for biomarker identification are the major influencing factors for the growth of the molecular diagnostics market.
As awareness and interest among patients for personalized medicine increases, the use of molecular diagnostics and genetic testing is bound to grow in the near future. In a recent survey conducted by the United Health Center for Health Reform & Modernization, more than XX% respondents agreed that genetic testing allows physicians to offer personalized treatment. Personalized medicine also involves pharmacogenomic tests, also considered as molecular diagnostic tests. They ensure maximum efficacy and safety, and are used in association with a drug. This field of personalized medicine is called companion diagnostics. As these tests increase in number, the molecular diagnostics market will also grow. Industry experts comment that in the coming decade, there will only be a handful of drugs without associated diagnostic tests.
New genes and biomarkers are continuously being identified and clinically validated, increasing the number of different molecular diagnostic tests available. The biomarker discovery and identification market has been showcasing a high double-digit CAGR of XX% since the recent past, and will continue to display the same over the next five years, thus highlighting the potential for growth in molecular tests.
Market share analysis
Novartis, with its Vaccines and Diagnostics division that was established after the acquisition of Chiron, followed at the number two position with a XX% share in the global market. Chiron offers Novartis access to its blood testing business in molecular diagnostics. Novartis has gained this position with its Procleix portfolio of systems, assays, and software. The company is also actively following a strategy of developing partnerships and signing agreements globally to expand its reach in the MDx market. The company, along with Gen-Probe with which it has collaborated to develop and market molecular technologies, has captured about two-thirds of the global blood screening MDx market. Novartis also signed an agreement with Grifols in early 2011 and Cepheid in 2010 to market their molecular diagnostics products in the U.S.Gen-Probe (now a part of Hologic) closely followed Novartis occupying a XX% share with its market leadership in CT/NG assays. It also has a significant presence in virology assays for diagnosis of HPV, HCV, and HIV.
Qiagen accounted for a share about XX% of the global MDx market with its leadership in HPV testing with a share of about XX%. Abbott occupied XX% of the MDx market with its PCR portfolio for a gamut of infectious disease testing and oncology. BD and Cepheid followed with a share of about XX%. Cepheid is the world leader in MRSA testing accounting for a share of more than XX% with its Xpert product line.
Molecular diagnostic laboratories and tests
The number of laboratories performing molecular diagnostics tests in 2013 in U.S. was XX and is estimated to reach XX in 2018 with a CAGR of XX%. In Europe, XX laboratories were performing molecular diagnostics tests in 2013. These laboratories are expected to reach XX in 2018 with CAGR of XX%.
Global molecular diagnostics market, by application
The infectious diseases application is leading the global molecular diagnostics market. It commanded the largest share of XX% of the market in 2013, valued at $XX million and is expected to reach $XX million by 2018, at a CAGR of XX% from 2013 to 2018. The growth is due to the development of advanced new assays and technologies, unprecedented occurrence of infections, and rising awareness for the need to control widespread infectious diseases.
Infectious diseases
The CT/NG tests market size, in terms of value, is estimated to grow from $XX million in 2013 to $XX million by 2018, at a CAGR of XX%. The markets for MRSA and HPV testing are estimated to grow at higher CAGRs of XX% and XX%, respectively from 2013 to 2018. This growth is attributed to the increasing test volumes of MRSA and HPV due to extensive screening programs in the U.S.
Global molecular diagnostics market, by technology
Molecular diagnostic tests are widely preferred for the detection of various pathogenic mutations in DNA/RNA samples in order to facilitate, diagnose, provide a prognosis, and monitor an individual’s response to therapy. These instruments leverage multiple technologies to identify genetic variations. The major molecular diagnostic technologies studied in this report include polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), microarray, hybridization, DNA sequencing, and next-generation sequencing (NGS). The other technologies associated with molecular diagnostics (MDx), but not as significant as the ones mentioned above, are electrophoresis, flow cytometry, and mass spectrometry.
PCR accounted for the largest share of XX% of the global MDx market in 2013, followed by INAAT (XX%) and hybridization (XX%). In the coming years, the MDx market will be driven by the microarray technology segment, which is poised to grow at a CAGR of XX% from 2013 to 2018.
Global molecular diagnostics market, by product type
The reagents segment accounted for the largest share of the molecular diagnostics market size, in terms of value, in 2013. This segment is expected to reach $XX million by 2018, at a CAGR of XX% from 2013 to 2018. As reagents are consumables, the growth in this market is attributed to the increase in the volumes of molecular diagnostic tests. The molecular diagnostics instruments market size is estimated to grow at a CAGR of XX% from 2013 to 2018.
Instruments
The instruments market accounted for a XX% share of the molecular diagnostics market in 2013. This market is vast, consisting of different technologies such as polymerase chain reaction, DNA sequencing, hybridization, electrophoresis, mass spectrometry, flow cytometry, and so on. The instruments used as platforms for molecular diagnostic test include amplifiers, thermal cyclers, DNA sequencers, DNA analyzers, and electrophoresis instruments, among others.
The instruments market is growing at a steady pace due to the continuous requirement for biotechnology instruments in laboratories, pharmaceutical, and biotechnology companies. The molecular diagnostic instrument market size, in terms of value, is poised to grow from $XX million in 2013 to $XX million by 2018, at a CAGR of XX% from 2013 to 2018. Automated and advanced instruments with high-throughput capacities, increase in number of biotechnology firms across the world, advances in life science research and technology innovations with human genome mapping, and emergence of omics technologies have enabled industry growth.
Geographic analysis
In this report, the molecular diagnostics market is divided into four major geographies, namely, North America, Europe, Asia, and the Rest of the World (RoW). The global molecular diagnostics market was valued at $XX million in 2013; North America was the largest market with a share of XX%, followed by Europe. In the next five years, the Asian region is estimated to register the highest CAGR of XX%, primarily due to the increasing investments by major players.
New product launch
Driven by research and innovation in the molecular diagnostics market, new product launch accounted for XX% all the strategies adopted by players to achieve growth in this market. Product launch proved to be very efficient in enhancing the company’s growth. This strategy mainly helped in increasing the customer base and application areas. Major players such as Becton, Dickinson and Company (U.S.), QIAGEN (Germany) and Roche (Switzerland) implemented this strategy successfully.
